ZBH Stock Analysis: Zimmer Biomet Holdings | NYSE
Medical Devices | NYSE, USA | Market Cap: 17.263m USD | 12M Return: -3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 196M
EPS Trend: 18.0%
Qual. Beats: 1
Rev. Trend: 97.7%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Zimmer Biomet Holdings (NYSE: ZBH) is a global medical technology company that designs, manufactures, and markets orthopedic reconstructive products, including knee and hip implants, as well as sports medicine, biologics, trauma, and craniomaxillofacial and thoracic (CMFT) products. The company sells to orthopedic surgeons, neurosurgeons, hospitals, and other healthcare institutions, and increasingly bundles its hardware with digital and robotic platforms such as the ROSA Robot for knee arthroplasty and the ZBEdge data platform.
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet was renamed from Zimmer Holdings in 2015 following the combination with Biomet. The company is classified as a large-cap U.S. health care equipment issuer within the GICS Health Care sector, operating in the mature, heavily regulated orthopedic medical device industry, which is characterized by long product development cycles, surgeon-driven adoption, and a competitive landscape dominated by a small group of global players.
- Knee and hip procedure volumes rebound with elective surgery demand
- ROSA Robot adoption expands margins through premium digital pricing
- Stryker and J&J competition pressures orthopedic market share growth
| Net Income: 761.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.00 > 1.0 |
| NWC/Revenue: 24.95% < 20% (prev 42.80%; Δ -17.85% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.67b > Net Income 761.3m |
| Net Debt (7.05b) to EBITDA (2.21b): 3.19 < 3 |
| Current Ratio: 1.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.8m) vs 12m ago -1.95% < -2% |
| Gross Margin: 70.03% > 18% (prev 71.05%; Δ -1.02% > 0.5%) |
| Asset Turnover: 37.45% > 50% (prev 34.70%; Δ 2.75% > 0%) |
| Interest Coverage Ratio: 4.08 > 6 (EBIT TTM 1.20b / Interest Expense TTM 295.4m) |
| A: 0.09 (Total Current Assets 4.96b - Total Current Liabilities 2.86b) / Total Assets 22.7b |
| B: 0.52 (Retained Earnings 11.8b / Total Assets 22.7b) |
| C: 0.05 (EBIT TTM 1.20b / Avg Total Assets 22.5b) |
| D: 1.26 (Book Value of Equity 12.7b / Total Liabilities 10.0b) |
| Altman-Z'' = 3.99 = AA |
| DSRI: 1.03 (Receivables 1.73b/1.53b, Revenue 8.41b/7.70b) |
| GMI: 1.01 (GM 71.05% / 70.03%) |
| AQI: 1.04 (AQ_t 0.68 / AQ_t-1 0.65) |
| SGI: 1.09 (Revenue 8.41b / 7.70b) |
| TATA: -0.04 (NI 761.3m - CFO 1.67b) / TA 22.7b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 91.34 with a total of 1,221,044 shares traded. Over the past week, the price has changed by +4.42%, over one month by +3.87%, over three months by -1.65% and over the past year by -2.99%.
Current recommended Stop Loss: 87.90 (which is 3.8% or 1.2 ATR below the current price).
Zimmer Biomet Holdings has received a consensus analysts rating of 3.45. Therefore, it is recommended to hold ZBH.
- StrongBuy: 5
- Buy: 6
- Hold: 16
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 98.1 | 7.3% |
P/E Trailing = 22.6472
P/E Forward = 10.4822
P/S = 2.0529
P/B = 1.3366
P/EG = 0.6205
Revenue TTM = 8.41b USD
EBIT TTM = 1.20b USD
EBITDA TTM = 2.21b USD
Long Term Debt = 6.30b USD (from longTermDebt, last quarter)
Short Term Debt = 1.18b USD (from shortTermDebt, last quarter)
Debt = 7.47b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.05b USD (calculated: Debt 7.47b - CCE 424.2m)
Enterprise Value = 24.3b USD (17.3b + Debt 7.47b - CCE 424.2m)
Interest Coverage Ratio = 4.08 (Ebit TTM 1.20b / Interest Expense TTM 295.4m)
EV/FCF = 13.24x (Enterprise Value 24.3b / FCF TTM 1.84b)
FCF Yield = 7.55% (FCF TTM 1.84b / Enterprise Value 24.3b)
FCF Margin = 21.83% (FCF TTM 1.84b / Revenue TTM 8.41b)
Net Margin = 9.05% (Net Income TTM 761.3m / Revenue TTM 8.41b)
Gross Margin = 70.03% ((Revenue TTM 8.41b - Cost of Revenue TTM 2.52b) / Revenue TTM)
Gross Margin QoQ = 72.39% (prev 64.68%)
Tobins Q-Ratio = 1.07 (Enterprise Value 24.3b / Total Assets 22.7b)
Interest Expense / Debt = 3.95% (Interest Expense 295.4m / Debt 7.47b)
Taxrate = 15.76% (142.3m / 903.1m)
NOPAT = 1.01b (EBIT 1.20b * (1 - 15.76%))
Current Ratio = 1.73 (Total Current Assets 4.96b / Total Current Liabilities 2.86b)
Debt / Equity = 0.59 (Debt 7.47b / totalStockholderEquity, last quarter 12.7b)
Debt / EBITDA = 3.19 (Net Debt 7.05b / EBITDA 2.21b)
Debt / FCF = 3.84 (Net Debt 7.05b / FCF TTM 1.84b)
Total Stockholder Equity = 12.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.39% (Net Income 761.3m / Total Assets 22.7b)
RoE = 6.01% (Net Income TTM 761.3m / Total Stockholder Equity 12.7b)
RoCE = 6.35% (EBIT 1.20b / Capital Employed (Equity 12.7b + L.T.Debt 6.30b))
RoIC = 4.92% (NOPAT 1.01b / Invested Capital 20.6b)
WACC = 6.72% (E(17.3b)/V(24.7b) * Re(8.19%) + D(7.47b)/V(24.7b) * Rd(3.95%) * (1-Tc(0.16)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.11 | Cagr: -2.78%
[DCF] Terminal Value 77.97% ; FCFF base≈1.64b ; Y1≈1.88b ; Y5≈2.77b
[DCF] Fair Price = 178.9 (EV 41.7b - Net Debt 7.05b = Equity 34.6b / Shares 193.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 17.98 | EPS CAGR: 1.19% | SUE: 4.0 | # QB: 1
Revenue Correlation: 97.71 | Revenue CAGR: 5.33% | SUE: 1.40 | # QB: 2
EPS current Quarter (2026-06-30): EPS=2.01 | Chg30d=-0.02% | Revisions=+0% | Analysts=24
EPS next Quarter (2026-09-30): EPS=1.88 | Chg30d=-0.05% | Revisions=-88% | Analysts=23
EPS current Year (2026-12-31): EPS=8.48 | Chg30d=+0.00% | Revisions=+50% | GrowthEPS=+3.4% | GrowthRev=+3.8%
EPS next Year (2027-12-31): EPS=8.99 | Chg30d=-0.17% | Revisions=+17% | GrowthEPS=+6.0% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: -42% (up=9, down=24)